Perspective Therapeutics CATX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $53.97M+76.2% | $30.63M+14.4% | $26.76M-7.2% | $28.85M-35.0% | $44.41M-27.9% | ||
| $216.96M+90.1% | $114.11M-22.6% | $147.38M-9.4% | $162.73M-2.7% | $167.3M+1.2% | ||
| —— | —— | —— | $0— | $0— | ||
| $58K+867% | $6K-96.6% | $179K-20.4% | $225K+188% | $78K-32.8% | ||
| $4.37M+19.7% | $3.65M-12.9% | $4.18M+0.7% | $4.16M+4.9% | $3.96M-4.0% | ||
| $275.35M+85.6% | $148.39M-16.9% | $178.5M-8.9% | $195.96M-9.2% | $215.74M-6.7% | ||
| $92.48M+20.7% | $76.6M+19.0% | $64.35M+2.8% | $62.6M+2.2% | $61.25M+6.8% | ||
| $2.44M+62.9% | $1.5M-2.3% | $1.54M-13.1% | $1.77M-11.4% | $1.99M-10.0% | ||
| —— | —— | —— | —— | —— | ||
| $40M0.0% | $40M-20.0% | $50M0.0% | $50M0.0% | $50M0.0% | ||
| $490K+0.8% | $486K+11.0% | $438K+9.2% | $401K+9.6% | $366K-9.6% | ||
| $410.77M+53.9% | $266.97M-9.4% | $294.83M-5.1% | $310.73M-5.7% | $329.35M-3.4% | ||
| $26.49M+29.1% | $20.51M+56.0% | $13.15M+86.5% | $7.05M-19.3% | $8.73M-15.6% | ||
| $3.88M-48.2% | $7.49M+11.6% | $6.71M+33.2% | $5.04M+73.0% | $2.91M— | ||
| $1.07M+71.6% | $623K-11.5% | $704K-16.9% | $847K-13.6% | $980K+2.4% | ||
| —— | —— | —— | —— | —— | ||
| $31.49M+9.8% | $28.68M+39.1% | $20.62M+58.8% | $12.99M+2.4% | $12.68M-30.4% | ||
| $1.55M-1.0% | $1.57M-0.9% | $1.58M-0.9% | $1.6M-0.9% | $1.61M-0.9% | ||
| $1.55M+54.4% | $1.01M+3.5% | $971K-9.3% | $1.07M-8.8% | $1.17M-17.8% | ||
| $2.62M+61.0% | $1.63M-2.8% | $1.68M-12.7% | $1.92M-11.0% | $2.15M-9.7% | ||
| $437K+13.2% | $386K+12.9% | $342K+20.4% | $284K+95.9% | $145K— | ||
| $63.33M+5.7% | $59.94M+13.9% | $52.61M+16.8% | $45.03M+0.7% | $44.7M-11.4% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $114K+54.1% | $74K0.0% | $74K0.0% | $74K+1.4% | $73K+4.3% | ||
| $708.58M+30.8% | $541.69M+0.4% | $539.38M+0.4% | $537M+0.5% | $534.45M+2.3% | ||
| -$361.03M-7.8% | -$334.84M-12.6% | -$297.35M-9.6% | -$271.38M-8.6% | -$249.9M-7.8% | ||
| -$226K-305% | $110K-3.5% | $114K— | —— | —— | ||
| $347.44M+67.8% | $207.03M-14.5% | $242.22M-8.8% | $265.69M-6.7% | $284.65M-2.1% | ||
| $410.77M+53.9% | $266.97M-9.4% | $294.83M-5.1% | $310.73M-5.7% | $329.35M-3.4% | ||
| $490K+0.8% | $486K+11.0% | $438K+9.2% | $401K+9.6% | $366K-9.6% | ||
| $40M0.0% | $40M-20.0% | $50M0.0% | $50M0.0% | $50M0.0% | ||
| $40M0.0% | $40M-20.0% | $50M0.0% | $50M0.0% | $50M0.0% | ||
| $40M0.0% | $40M-20.0% | $50M0.0% | $50M0.0% | $50M0.0% | ||
| $40M0.0% | $40M-20.0% | $50M0.0% | $50M0.0% | $50M0.0% | ||
| $2.44M+62.9% | $1.5M-2.3% | $1.54M-13.1% | $1.77M-11.4% | $1.99M-10.0% | ||
| $2.44M+62.9% | $1.5M-2.3% | $1.54M-13.1% | $1.77M-11.4% | $1.99M-10.0% | ||
| $490K+0.8% | $486K+11.0% | $438K+9.2% | $401K+9.6% | $366K-9.6% | ||
| $216.96M+90.1% | $114.11M-22.6% | $147.38M-9.4% | $162.73M-2.7% | $167.3M+1.2% | ||
| $2.44M+62.9% | $1.5M-2.3% | $1.54M-13.1% | $1.77M-11.4% | $1.99M-10.0% | ||
| $490K+0.8% | $486K+11.0% | $438K+9.2% | $401K+9.6% | $366K-9.6% | ||
| $3.88M-48.2% | $7.49M+11.6% | $6.71M+33.2% | $5.04M+73.0% | $2.91M— | ||
| $26.49M+29.1% | $20.51M+56.0% | $13.15M+86.5% | $7.05M-19.3% | $8.73M-15.6% | ||
| $3.88M-48.2% | $7.49M+11.6% | $6.71M+33.2% | $5.04M+73.0% | $2.91M— | ||
| $56K0.0% | $56K+1.8% | $55K+1.9% | $54K+1.9% | $53K+1.9% | ||
| $56K0.0% | $56K+1.8% | $55K+1.9% | $54K+1.9% | $53K+1.9% | ||
| $4.18M+30.6% | $3.2M-1.9% | $3.26M-7.3% | $3.52M-6.6% | $3.77M-6.1% | ||
| $708.58M+30.8% | $541.69M+0.4% | $539.38M+0.4% | $537M+0.5% | $534.45M+2.3% | ||
| $114K+54.1% | $74K0.0% | $74K0.0% | $74K+1.4% | $73K+4.3% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $26.6M0.0% | $26.6M0.0% | $26.6M0.0% | $26.6M0.0% | $26.6M0.0% | ||
| $1.7M0.0% | $1.7M-31.8% | $2.5M0.0% | $2.5M0.0% | $2.5M0.0% | ||
| $40M0.0% | $40M-20.0% | $50M0.0% | $50M0.0% | $50M0.0% | ||
| $1.55M-1.0% | $1.57M-0.9% | $1.58M-0.9% | $1.6M-0.9% | $1.61M-0.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Perspective Therapeutics's total assets?
- Perspective Therapeutics (CATX) holds $410.8M in total assets, up 24.7% year over year.
- How much debt does Perspective Therapeutics have?
- Perspective Therapeutics carries $4.2M in total debt against $347.4M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Perspective Therapeutics have?
- Perspective Therapeutics holds $54.0M in cash and equivalents.
- Can Perspective Therapeutics cover its short-term obligations?
- Its current ratio is 8.75 — current assets exceed current liabilities.
- Where does Perspective Therapeutics's balance sheet data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
